INDIVIOR PHARMACEUTICALS INC

Indivior insider buys signal confidence—chief accountant buys 1,500 shares amid 75% earnings growth, suggesting a solid long‑term outlook for investors.

Indivior insider sale: Chief Scientific Officer’s July 10 trade is routine, not a red flag—yet investors should watch pipeline milestones and earnings for upside.

Indivior insider trades reveal a cautious confidence amid FDA scrutiny, debt refinancing, and digital‑therapeutic competition—key insights for investors seeking the next mid‑cap move.